ClinicalTrials.gg
RecruitingNCT07414342Updated Feb 17, 2026

Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

An interventional study of RENATUS® TAVR in Severe Aortic Stenosis, sponsored by Beijing Balance Medical Technology Co., Ltd. Recruiting at 4 sites in China. Open to participants aged 60 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Beijing Balance Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
60 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
4th of 47
800 · median 120
Started
2026
with 6 others
No phase
37 of 69
20 open now
Primary completion
2027-09
later than 32 of 50 live
Registered
62nd of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 4th largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 with no phase, reaches primary completion later than 32 of the 50 other live ones, and was the 62nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 60 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, non-randomized, observational, post-market follow-up trial designed to evaluate the safety and efficacy of the RENATUS® Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.

03

Conditions studied

  • Severe Aortic Stenosis
04

Who can participate

Ages eligible
60 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients deemed eligible for TAVR by the treating physician, including those at high, intermediate, or low surgical risk, with a calculated Society of Thoracic Surgeons (STS) risk score;
  2. Symptomatic patients with severe aortic stenosis, defined by echocardiography as having at least one of the following:

    • Mean transvalvular pressure gradient ≥40 mmHg (1 mmHg = 0.133 kPa),
    • Peak aortic jet velocity ≥4.0 m/s,
    • Aortic valve area \<1.0 cm², or Indexed effective orifice area \<0.6 cm²/m²;
  3. Patients who understand the purpose of the trial, voluntarily agree to participate, provide written , and are willing to undergo required examinations and clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a of ≤1 year following prosthetic valve implantation;
  2. Patients who have experienced an acute myocardial infarction or undergone any therapeutic cardiac surgery within the past month;
  3. Patients with minimal or no calcification of the aortic annulus;
  4. Patients with aortic root anatomy or pathology deemed unsuitable for prosthetic valve implantation;
  5. Patients with multivalvular disease (severe stenosis and/or regurgitation);
  6. Patients with hematologic cachexia, including leukopenia (WBC \<3×10⁹/L), acute anemia ( \<90 g/L), thrombocytopenia ( \<50×10⁹/L), bleeding diathesis, or coagulopathy;
  7. Patients with untreated coronary artery disease requiring revascularization;
  8. Patients with obstructive hypertrophic cardiomyopathy;
  9. Patients with severe left ventricular dysfunction ( \<20%);
  10. Patients with severe right ventricular dysfunction;
  11. Patients with intracardiac masses, fresh thrombi, or vegetations detected by echocardiography;
  12. Patients unable to tolerate anticoagulant or antiplatelet therapy;
  13. Patients who have experienced a cerebrovascular accident (CVA)-including ischemic or hemorrhagic stroke-within the past 3 months;
  14. Patients with decompensated renal insufficiency;
  15. Patients with active infective endocarditis or other active infections;
  16. Patients with untreated conduction system disease requiring pacemaker implantation;
  17. Patients who have participated in another drug or medical device clinical trial and have not yet reached the primary endpoint assessment timepoint;
  18. Any other condition, as determined by the investigator, that renders the patient unsuitable for transcatheter aortic valve intervention.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    RENATUS® TAVR treatment

    Device: RENATUS® TAVR

Interventions

  • DeviceRENATUS® TAVR

    RENATUS® Transcatheter Aortic Valve System,an approved marketed TAVR

06

What researchers measure

Primary outcomes

  1. Cumulative all-cause mortality (all-cause mortality includes both cardiac and non-cardiac deaths)

    Time frame: 1 year post-procedure

Secondary outcomes

  1. Procedural success rate

    Time frame: Perioperative

  2. Device success rate;

    Time frame: Perioperative

  3. All-cause mortality at 1, 3, 5, and 10 years

    Time frame: 1, 3, 5, and 10 years

Other outcomes

  1. Transvalvular pressure gradient at 30 days and 1 year post-procedure;

    Time frame: 30 days and 1 year post-procedure;

  2. Valve performance changes: valvular regurgitation, paravalvular leak, etc.;

    Time frame: 1 year post-procedure

  3. Incidence of major adverse cardiovascular and cerebrovascular events (MACCE): death, disabling stroke, myocardial infarction, arrhythmia, conduction block, pacemaker implantation, etc.

    Time frame: 1, 3, 5, and 10 years

  4. Incidence of valve-related complications: infective endocarditis, hemolysis, valve stenosis, prosthetic valve failure, and other manifestations of valve dysfunction

    Time frame: 1, 3, 5, and 10 years

  5. Reoperation rate;

    Time frame: 1, 3, 5, and 10 years

  6. NYHA functional classification;

    Time frame: 1 year post-procedure

  7. Patient-reported quality of life score.

    Time frame: 1 year post-procedure

  8. Hospital readmission rate;

    Time frame: 1, 3, 5, and 10 years

  9. Anticoagulation-related complications.

    Time frame: 1, 3, 5, and 10 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Sep 2027, 19 months later.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 19 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 17, 2026
StartEst.
Feb 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2037
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414342
Lead sponsor
Beijing Balance Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2037 (estimated)
Last update
Feb 17, 2026

Study contacts

Lai Yongqiang
Contact
yongqianglai@outlook.com
010-64456376

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion